Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

LGD-1069 to enter pivotal U.S. trials

Aug. 30, 1996

AG-2034 granted approval for U.S. phase I initiation

Aug. 30, 1996

Phase III trial on Onconase combination initiated

Aug. 30, 1996

Novel antitumor compounds claimed by Kyorin/Sagami

Aug. 23, 1996

Lisofylline undergoes phase III in cancer patients

Aug. 23, 1996

Ethyol extended labeling approved

Aug. 23, 1996

Accelerated drug development program for Oxi-104

Aug. 23, 1996

Antineoplastic agents from Japan Energy

Aug. 23, 1996

VIMRxyn to undergo phase I in glioma patients

Aug. 23, 1996

NeXstar describes ELONA and significance for VEGF inhibitor development

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.